FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2296187722> ?p ?o ?g. }

• W2296187722 endingPage "1254" @default.
• W2296187722 startingPage "1249" @default.
• W2296187722 abstract "Essentials•Disorders of hemostasis can lead to delayed and defective wound healing.•In hemophilia B (HB) mice, 7 days of Factor (F)IX or VIIa are needed to normalize wound healing.•One dose of a highly active FVIIa variant (DVQ) restored normal wound closure time in HB mice.•Coagulation factors with enhanced activity may acquire biological effects not due to hemostasis.AcknowledgementsThe authors would like to acknowledge the outstanding technical assistance of J. Brock and A. Crabtree.Novo NordiskSummary: IntroductionWe have previously reported that hemophilia B (HB) mice have delayed healing of cutaneous wounds and alterations in wound histology. Administration of a single dose of either factor IX or recombinant activated FVII (rFVIIa) (NovoSeven) prior to wounding did not improve wound closure time or histology. The FVIIa analog DVQ (V158D, E296V and M298Q mutations) was designed to have higher tissue factor‐independent activity than rVIIa. We hypothesized that a single dose of DVQ would be more effective in restoring wound healing in HB mice.MethodsCutaneous punch wounds were made on the backs of HB and wild‐type mice, and the time to wound closure was monitored. HB mice were treated with a dose of rFVIIa (10 mg kg−1) or DVQ (1 mg kg−1) that corrected the tail bleeding time. Skin samples were taken at various time points after wounding, fixed, and stained, and the histology was examined.ResultsAs previously reported, wound closure times in HB mice given one dose of rFVIIa were not improved over those in untreated HB mice. Surprisingly, healing times in HB mice treated with an equally hemostatic dose of DVQ were normalized to that in wild‐type mice. However, DVQ did not correct all histologic abnormalities in HB mice.ConclusionsAs the doses of DVQ and rFVIIa were chosen to support comparable levels of hemostasis, our data suggest that the improved healing seen with DVQ is not solely attributable to its hemostatic activity. It is possible that the improved wound healing arises through the effect of DVQ on cell signaling mechanisms. Essentials•Disorders of hemostasis can lead to delayed and defective wound healing.•In hemophilia B (HB) mice, 7 days of Factor (F)IX or VIIa are needed to normalize wound healing.•One dose of a highly active FVIIa variant (DVQ) restored normal wound closure time in HB mice.•Coagulation factors with enhanced activity may acquire biological effects not due to hemostasis.AcknowledgementsThe authors would like to acknowledge the outstanding technical assistance of J. Brock and A. Crabtree.Novo Nordisk •Disorders of hemostasis can lead to delayed and defective wound healing.•In hemophilia B (HB) mice, 7 days of Factor (F)IX or VIIa are needed to normalize wound healing.•One dose of a highly active FVIIa variant (DVQ) restored normal wound closure time in HB mice.•Coagulation factors with enhanced activity may acquire biological effects not due to hemostasis. The authors would like to acknowledge the outstanding technical assistance of J. Brock and A. Crabtree.Novo Nordisk We have previously reported that hemophilia B (HB) mice have delayed healing of cutaneous wounds and alterations in wound histology. Administration of a single dose of either factor IX or recombinant activated FVII (rFVIIa) (NovoSeven) prior to wounding did not improve wound closure time or histology. The FVIIa analog DVQ (V158D, E296V and M298Q mutations) was designed to have higher tissue factor‐independent activity than rVIIa. We hypothesized that a single dose of DVQ would be more effective in restoring wound healing in HB mice. Cutaneous punch wounds were made on the backs of HB and wild‐type mice, and the time to wound closure was monitored. HB mice were treated with a dose of rFVIIa (10 mg kg−1) or DVQ (1 mg kg−1) that corrected the tail bleeding time. Skin samples were taken at various time points after wounding, fixed, and stained, and the histology was examined. As previously reported, wound closure times in HB mice given one dose of rFVIIa were not improved over those in untreated HB mice. Surprisingly, healing times in HB mice treated with an equally hemostatic dose of DVQ were normalized to that in wild‐type mice. However, DVQ did not correct all histologic abnormalities in HB mice. As the doses of DVQ and rFVIIa were chosen to support comparable levels of hemostasis, our data suggest that the improved healing seen with DVQ is not solely attributable to its hemostatic activity. It is possible that the improved wound healing arises through the effect of DVQ on cell signaling mechanisms." @default.
• W2296187722 created "2016-06-24" @default.
• W2296187722 creator A5012832785 @default.
• W2296187722 creator A5051841089 @default.
• W2296187722 creator A5081018170 @default.
• W2296187722 creator A5087076296 @default.
• W2296187722 date "2016-06-01" @default.
• W2296187722 modified "2023-10-13" @default.
• W2296187722 title "An activated factor VII variant with enhanced tissue factor‐independent activity speeds wound healing in a mouse hemophilia B model" @default.
• W2296187722 cites W1255418244 @default.
• W2296187722 cites W1525674540 @default.
• W2296187722 cites W1569674809 @default.
• W2296187722 cites W1897419532 @default.
• W2296187722 cites W2019573005 @default.
• W2296187722 cites W2024710679 @default.
• W2296187722 cites W2041404288 @default.
• W2296187722 cites W2045798059 @default.
• W2296187722 cites W2046936517 @default.
• W2296187722 cites W2057877210 @default.
• W2296187722 cites W2065397776 @default.
• W2296187722 cites W2073227556 @default.
• W2296187722 cites W2077777862 @default.
• W2296187722 cites W2087677741 @default.
• W2296187722 cites W2090723639 @default.
• W2296187722 cites W2098188159 @default.
• W2296187722 cites W2099079542 @default.
• W2296187722 cites W2109003412 @default.
• W2296187722 cites W2126662679 @default.
• W2296187722 cites W2129609495 @default.
• W2296187722 cites W2134428975 @default.
• W2296187722 doi "https://doi.org/10.1111/jth.13311" @default.
• W2296187722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26952654" @default.
• W2296187722 hasPublicationYear "2016" @default.
• W2296187722 type Work @default.
• W2296187722 sameAs 2296187722 @default.
• W2296187722 citedByCount "2" @default.
• W2296187722 countsByYear W22961877222018 @default.
• W2296187722 countsByYear W22961877222023 @default.
• W2296187722 crossrefType "journal-article" @default.
• W2296187722 hasAuthorship W2296187722A5012832785 @default.
• W2296187722 hasAuthorship W2296187722A5051841089 @default.
• W2296187722 hasAuthorship W2296187722A5081018170 @default.
• W2296187722 hasAuthorship W2296187722A5087076296 @default.
• W2296187722 hasBestOaLocation W22961877221 @default.
• W2296187722 hasConcept C104317684 @default.
• W2296187722 hasConcept C126322002 @default.
• W2296187722 hasConcept C141071460 @default.
• W2296187722 hasConcept C142724271 @default.
• W2296187722 hasConcept C185592680 @default.
• W2296187722 hasConcept C186738567 @default.
• W2296187722 hasConcept C203014093 @default.
• W2296187722 hasConcept C2777928079 @default.
• W2296187722 hasConcept C2778382381 @default.
• W2296187722 hasConcept C2778589496 @default.
• W2296187722 hasConcept C2778961111 @default.
• W2296187722 hasConcept C2780269544 @default.
• W2296187722 hasConcept C2780930249 @default.
• W2296187722 hasConcept C2781221834 @default.
• W2296187722 hasConcept C2908626413 @default.
• W2296187722 hasConcept C2993873987 @default.
• W2296187722 hasConcept C40767141 @default.
• W2296187722 hasConcept C55493867 @default.
• W2296187722 hasConcept C57742111 @default.
• W2296187722 hasConcept C71924100 @default.
• W2296187722 hasConcept C98274493 @default.
• W2296187722 hasConceptScore W2296187722C104317684 @default.
• W2296187722 hasConceptScore W2296187722C126322002 @default.
• W2296187722 hasConceptScore W2296187722C141071460 @default.
• W2296187722 hasConceptScore W2296187722C142724271 @default.
• W2296187722 hasConceptScore W2296187722C185592680 @default.
• W2296187722 hasConceptScore W2296187722C186738567 @default.
• W2296187722 hasConceptScore W2296187722C203014093 @default.
• W2296187722 hasConceptScore W2296187722C2777928079 @default.
• W2296187722 hasConceptScore W2296187722C2778382381 @default.
• W2296187722 hasConceptScore W2296187722C2778589496 @default.
• W2296187722 hasConceptScore W2296187722C2778961111 @default.
• W2296187722 hasConceptScore W2296187722C2780269544 @default.
• W2296187722 hasConceptScore W2296187722C2780930249 @default.
• W2296187722 hasConceptScore W2296187722C2781221834 @default.
• W2296187722 hasConceptScore W2296187722C2908626413 @default.
• W2296187722 hasConceptScore W2296187722C2993873987 @default.
• W2296187722 hasConceptScore W2296187722C40767141 @default.
• W2296187722 hasConceptScore W2296187722C55493867 @default.
• W2296187722 hasConceptScore W2296187722C57742111 @default.
• W2296187722 hasConceptScore W2296187722C71924100 @default.
• W2296187722 hasConceptScore W2296187722C98274493 @default.
• W2296187722 hasFunder F4320322436 @default.
• W2296187722 hasIssue "6" @default.
• W2296187722 hasLocation W22961877221 @default.
• W2296187722 hasLocation W22961877222 @default.
• W2296187722 hasLocation W22961877223 @default.
• W2296187722 hasLocation W22961877224 @default.
• W2296187722 hasOpenAccess W2296187722 @default.
• W2296187722 hasPrimaryLocation W22961877221 @default.
• W2296187722 hasRelatedWork W1897057798 @default.
• W2296187722 hasRelatedWork W1963828782 @default.
• W2296187722 hasRelatedWork W1968972929 @default.
• W2296187722 hasRelatedWork W2023412739 @default.

• next